Analyst consensus

The consensus estimates are collected by the company and based on the estimates of brokerage firms covering GSK. Please ensure you have read and acknowledged the disclaimer prior to reviewing the information provided.

  • Q3 2022 Income statement and product revenue figures are as at 24/10/2022
  • FY 2022-2026 Income statement and product revenue figures are as at 06/09/2022
Income Statement

 

£m (unless stated) Q322 Q322 n= 2022 2023 2024 2025 2026 2022-2026 n=
Turnover - Specialty ex pandemic solutions 2,336 18 8,718 9,909 10,965 11,953 12,794 14
Turnover - General Medicines 2,511 18 9,805 9,765 9,664 9,560 9,463 14
Turnover - Vaccines ex pandemic solutions 2,409 18 7,668 8,659 9,607 10,541 11,287 14
Turnover - GSK excluding pandemic solutions 7,256 18 26,191 28,334 30,236 32,054 33,544 14
Turnover - pandemic solutions 63 18 1,899 155 98 67 52 14
Turnover - GSK 7,319 18 28,090 28,489 30,334 32,120 33,596 14
Cost of sales (1,984) 18 (8,403) (7,777) (8,131) (8,534) (8,840) 14
Selling, general and administration (1,931) 18 (7,688) (7,953) (8,259) (8,531) (8,727) 14
Research and Development (1,282) 18 (4,934) (5,186) (5,431) (5,668) (5,836) 14
Royalty income 175 18 643 711 430 464 489 14
Operating profit 2,297 18 7,708 8,285 8,942 9,852 10,682 14
Net finance costs (185) 18 (763) (691) (651) (618) (590) 14
Associates 2 18 3 4 4 4 4 14
Profit before tax 2,114 18 6,948 7,598 8,295 9,237 10,097 14
Taxation (344) 18 (1,117) (1,257) (1,384) (1,547) (1,693) 14
Tax Rate 16.3% 18 16.1% 16.5% 16.7% 16.7% 16.8% 14
Profit after tax  1,770 18 5,831 6,340 6,911 7,691 8,403 14
Minority interests (154) 18 (611) (648) (690) (728) (757) 14
Profit attributable to shareholders 1,616 18 5,220 5,693 6,221 6,963 7,646 14
WANS (m) 4,027 18 4,025 4,046 4,062 4,078 4,089 14
Earnings per share (p) 40.1 18 129.7 140.7 153.2 170.8 187.0 14
Dividend per share (p) 13.6 11 58.5 56.8 59.8 63.1 66.1 13
Free Cash Flow n/a n/a 3,297 4,446 5,185 5,974 6,469 10
Net Debt n/a n/a (14,281) (11,550) (8,642) (3,941) (1,307) 12
                 
USD / GBP 1.19 18 1.25 1.22 1.22 1.22 1.22 14
EUR / GBP 1.17 17 1.18 1.17 1.18 1.18 1.18 14
JPY / GBP 162 14 160 163 163 163 163 11

The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Intron Health, Jefferies, JP Morgan, Morgan Stanley, Redburn, Shore Capital, Stifel, UBS, Wolfe Research

Specialty medicines

 

Turnover £m Q322 Q322 n= 2022 2023 2024 2025 2026 2022-2026 n=
                 
Tivicay 346 16 1,329 1,253 1,157 1,070 989 14
Triumeq 470 16 1,750 1,573 1,391 1,254 1,123 14
Juluca 157 17 606 660 692 717 737 14
Dovato 342 17 1,268 1,624 1,890 2,075 2,227 14
Dolutegravir based regimens 1,315 18 4,953 5,111 5,131 5,117 5,077 14
Cabenuva 93 18 303 542 791 1,041 1,244 14
Apretude 14 18 46 152 282 412 514 14
Cabotegravir +/- rilpivirine 107 18 349 693 1,073 1,453 1,758 14
Rukobia 24 17 87 125 154 176 197 14
Other HIV 26 17 103 89 82 83 94 n/a
HIV 1,472 18 5,492 6,019 6,440 6,829 7,126 14
                 
Benlysta 317 18 1,142 1,301 1,405 1,424 1,400 14
Nucala 368 18 1,406 1,567 1,673 1,743 1,780 14
                 
Zejula 128 18 479 583 666 752 831 14
Blenrep 37 18 131 208 287 358 424 14
Jemperli 7 18 26 60 95 129 158 14
                 
momelotinib - n/a - 36 99 175 255 13
daprodustat - n/a 14 105 204 297 367 13
                 
Specialty Medicines ex pandemic solutions 2,336 18 8,718 9,909 10,965 11,953 12,794 14
                 
Xevudy 60 18 1,884 144 67 46 37 14
                 
Specialty Medicines 2,396 18 10,602 10,053 11,032 11,999 12,831 14

 

The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Intron Health, Jefferies, JP Morgan, Morgan Stanley, Redburn, Shore Capital, Stifel, UBS, Wolfe Research

Vaccines

 

Turnover £m Q322 Q322 n= 2022 2023 2024 2025 2026 2022-2026 n=
Bexsero 254 16 735 792 819 840 858 14
Menveo 146 16 311 330 337 342 345 14
Other Meningitis 2 16 30 32 32 32 32 8
Meningitis 402 18 1,076 1,154 1,188 1,214 1,235 14
Fluarix/Flulaval 421 18 712 745 763 782 801 14
Shingrix 685 18 2,799 3,416 3,961 4,354 4,663 14
Boostrix 182 16 582 603 612 622 631 14
Cervarix 31 15 112 114 114 115 116 13
Hepatitis 167 16 564 618 644 666 682 14
Infanrix, Pediarix 167 16 577 584 583 583 584 14
Rotarix 163 16 553 574 585 596 606 14
Synflorix 68 16 332 334 329 321 314 14
Established Vaccines 901 18 3,080 3,192 3,224 3,262 3,292 14
RSV OA - n/a - 136 409 787 1,037 14
Vaccines ex pandemic solutions 2,409 18 7,668 8,659 9,607 10,541 11,287 14
Pandemic solutions 3 18 15 12 31 21 15 14
Vaccines 2,412 18 7,683 8,671 9,637 10,561 11,302 14

 

The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Intron Health, Jefferies, JP Morgan, Morgan Stanley, Redburn, Shore Capital, Stifel, UBS, Wolfe Research

General medicines

 

Turnover £m Q322 Q322 n= 2022 2023 2024 2025 2026 2022-2026 n=
Anoro 126 17 468 488 492 493 494 14
Arnuity 17 17 58 61 62 63 64 14
Avamys/Veramyst 64 16 302 274 251 235 222 13
Flixotide/Flovent 120 17 484 444 419 398 378 14
Incruse 55 17 212 219 224 227 232 14
Relvar/Breo 274 17 1,123 1,113 1,100 1,085 1,072 14
Seretide/Advair 282 17 1,130 1,013 913 829 759 14
Trelegy 480 17 1,743 2,082 2,324 2,515 2,677 14
Ventolin 181 17 715 676 642 612 584 14
Respiratory 1,625 17 6,360 6,484 6,533 6,554 6,571 14
Other General Medicines 886 17 3,445 3,281 3,132 3,006 2,892 14
                 
General Medicines 2,511 18 9,805 9,765 9,664 9,560 9,463 14

 

The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Intron Health, Jefferies, JP Morgan, Morgan Stanley, Redburn, Shore Capital, Stifel, UBS, Wolfe Research

Back to top